Full year 2016: Another year of double-digit sales growth for Tecan
(Thomson Reuters ONE) -
Tecan Group AG /
Full year 2016: Another year of double-digit sales growth for Tecan
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Financial results: full-year and second half of 2016
* Order entry of CHF 503.2 million (2015: CHF 465.0 million)
* Full-year growth of 6.9% in local currencies or 8.2% in Swiss francs
* Strong H2 growth in Life Sciences Business, supported by new products
* H2 growth in Partnering Business impacted by one large order shifted to
January 2017
* Sales of CHF 506.2 million (2015: CHF 440.3 million)
* Full-year growth of 13.5% in local currencies or 15.0% in Swiss francs
* Full-year organic growth of 8.2% in local currencies and 9.6% in Swiss
francs
* H2 sales growth of 12.2% in local currencies or 12.7% in Swiss francs
* Full-year operating profit before depreciation and amortization (EBITDA)
of CHF 89.0 million (2015: CHF 83.4 million)
* Reported EBITDA margin of 17.6% (2015: 18.9%), including acquisition-
related costs and reduced margins associated with the acquisition of
Sias AG
* Underlying EBITDA, excluding acquisition-related effects, of CHF 93.2
million
* Strong improvement in underlying EBITDA margin of 140 basis points to
19.5% (2015: 18.1%), driven by positive volume and price effects as well
as substantial efficiency improvements
* Full-year net profit of CHF 54.5 million below prior year due to integration
costs and non-operational effects (2015: CHF 57.1 million)
* Net profit margin including integration costs of 10.8% (2015: 13.0%)
* Earnings per share of CHF 4.74 (2015: CHF 5.05)
* Strong full-year cash flow from operating activities of CHF 118.8
million (2015: CHF 99.1 million) or 23.5% of sales (2015: 22.5%)
Operating highlights 2016 and other important information
* Significant increase in serial production of major platforms in the
Partnering Business
* Successful integration of Sias AG, which was acquired in November 2015
* Acquisition of SPEware Corporation in September 2016, a leading provider for
mass spectrometry sample preparation solutions
* Launch of additional important features for Fluent(®) next generation liquid
handling platforms as well as a new variant of the Spark(®) reader platform
* Unchanged dividend of CHF 1.75 per share proposed
Outlook 2017
* Full-year sales are forecast to increase by at least 6% in local currencies
* Reported EBITDA margin expected to further expand to at least 18% of sales,
including acquisition-related costs in a mid single-digit million Swiss
franc amount
Männedorf, Switzerland, March 15, 2017 - The Tecan Group (SIX Swiss Exchange:
TECN) today announced its financial results for full-year and second half of
2016.
Tecan CEO David Martyr commented: "I am pleased that we recorded another year of
double-digit sales growth and a further improvement in underlying profitability
during 2016. Importantly, we posted strong sales growth in both divisions and
all regions, with China being a specific highlight. Once again, the high
operating cash flow of over 23% of sales was particularly satisfactory.
Our new platforms had a strong market uptake, with Fluent quickly becoming the
industry-leading automation solution and Spark setting new standards for
multimode readers regarding sensitivity, speed and accuracy. In our Partnering
Business, we saw a substantial increase in serial production of major platforms
and we successfully concluded several new development agreements, providing the
basis for continued growth. We fully integrated Sias AG, which we acquired at
the end of 2015 and relocated our new colleagues and the production lines into
the Tecan site in Maennedorf. In August, we were delighted to announce the
acquisition of US-based SPEware Corporation, which further expands our solutions
offering into the sample preparation for mass spectrometry market," Martyr
continued.
Financial results full-year and second half of 2016
In the second half of 2016, order entry in the Life Science Business grew
strongly, however Partnering Business was affected by a large order which was
shifted by a corporate customer from December 2016 to January 2017. Despite this
timing effect, order entry in the second half overall increased by 2.8% in local
currencies and by 3.1% in Swiss francs against a strong base in the prior-year
period. For the full year, order entry increased by 6.9% in local currencies to
CHF 503.2 million (2015: CHF 465.0 million), corresponding to growth of 8.2%. On
an organic basis, order entry increased by 1.8% in local currencies and by 3.1%
in Swiss francs. Organic development only includes contributions from
acquisitions from those months in the reporting period that were already
included in the consolidated financial statements in the prior-year period.
Sales in the second half rose by 12.2% in local currencies and by 12.7% in Swiss
francs. This corresponds to organic sales growth of 7.3% in local currencies and
7.8% in Swiss francs. Sales in financial year 2016 increased by 13.5% in local
currencies and 15.0% in Swiss francs to CHF 506.2 million (2015: CHF 440.3
million), exceeding the CHF 500 million mark for the first time in the Company's
history. On an organic basis, sales grew by 8.2% in local currencies and 9.6% in
Swiss francs.
Operating profit before depreciation and amortization (earnings before interest,
taxes, depreciation and amortization; EBITDA) rose by 6.8% to CHF 89.0 million
in the fiscal year (2015: CHF 83.4 million). Including acquisition-related costs
from two recent transactions and reduced margins associated with the acquisition
of Sias AG, the EBITDA margin was 17.6% of sales (2015: 18.9%). By contrast, the
underlying EBITDA margin, excluding acquisition-related effects, improved by
140 basis points to 19.5% of sales, thereby comfortably delivering on the margin
commitment for the year of "at least 50 basis points". In 2015, the underlying
EBITDA margin reached 18.1% and excludes a one-time positive net impact mainly
from revised pension liabilities. The margin improvement in 2016 was driven by
positive volume and price effects as well as substantial efficiency improvements
in operations and in research and development.
Despite a higher operating result, net profit for the year 2016 was CHF 54.5
million and therefore below the prior-year period due to non-operational effects
(2015: CHF 57.1 million). In addition to acquisition-related costs, the
difference is due to the lack of the positive one-time effects from 2015, an
increase of the tax rate in 2016 to an again more normalized level and a lower
financial result due to currency hedging. The net profit margin therefore
reached 10.8% of sales (2015: 13.0%), while earnings per share were CHF 4.74
(2015: CHF 5.05)
Cash flow from operating activities grew strongly to CHF 118.8 million (2015:
CHF 99.1 million), including a further reimbursement of development costs by an
OEM partner. Thus, cash flow from operating activities corresponded to 23.5% of
sales.
Information by business segment
Life Sciences Business (end-customer business)
In the second half of the year, sales in the Life Sciences Business increased by
10.7% in local currencies and were 11.7% above the prior-year period in Swiss
francs. On an organic basis, excluding sales from SPEware in the last quarter,
sales in the second half grew by 7.5% in local currencies. Sales for the full
year totaled CHF 280.2 million, representing an increase of 8.6% in local
currencies and 10.7% in Swiss francs over the prior-year period (2015: CHF
253.0 million). On an organic basis, sales increased by 6.8% in local currencies
in 2016. The new Fluent and Spark platforms as well as recurring sales of
services, consumables and reagents made a considerable contribution to this
growth. Order entry in the Life Sciences Business again exceeded sales for the
full year and saw an acceleration in the second half, supported by a strong
market uptake of new products.
Operating profit before interest and taxes (EBIT) in the segment was CHF 45.7
million in the year under review (2015: CHF 45.4 million), corresponding to an
operating profit margin of 15.6% of sales (2015: 17.0%).
Partnering Business (OEM business)
Sales in the Partnering Business grew by 14.3% in local currencies as well as in
Swiss francs in the second half of 2016. On an organic basis, revenue rose by
7.0% in local currencies.
The Partnering Business generated sales of CHF 226.0 million in financial year
2016 (2015: CHF 187.3 million), which corresponds to an increase of 20.1% in
local currencies and 20.7% in Swiss francs. On an organic basis, sales increased
by 10.1% in local currencies.
Instrument platforms launched in recent years made a significant contribution to
the strong sales growth. Also, sales in China increased substantially, with
several local components and instrument customers now successfully
commercializing their respective platforms. Order entry in the Partnering
Business also grew at a solid rate for the full year 2016, albeit slowing down
in the second half as a large order was shifted by a corporate customer from
December 2016 to January 2017.
The segment's operating profit rose to CHF 33.8 million (2015: CHF 30.2
million), despite integration costs related to the Sias acquisition reaching a
mid single-digit million Swiss franc amount. Due to those acquisition-related
costs, operating profit margin was down on the prior-year period at 14.8% of
sales (2015: 16.0%).
Additional information
Regional development
In Europe, full-year sales in local currencies increased by 12.8% and by 13.3%
in Swiss francs. This growth was driven primarily by the Partnering Business,
both from the first-time contribution to sales from Sias products and strong
organic growth by major platforms.
In North America, sales grew by 7.6% in local currencies and 9.6% in Swiss
francs. The Life Sciences and Partnering Business recorded solid growth in this
region.
In Asia, Tecan once again achieved a considerable increase in sales of 27.0% in
local currencies and 30.2% in Swiss francs. Both segments posted a double-digit
increase in organic sales, which was further supported by a first-time
contribution to sales by Sias products. Growth in China, where sales grew with
more than 50%, was particularly pleasing, bringing the total business to close
to CHF 50 million in the year.
Recurring sales of services, consumables and reagents
In 2016, recurring sales of services and consumables increased by 12.5% in local
currencies and 14.1% in Swiss francs, and therefore amounted to 37.6% of total
sales (2015: 37.8%). Services (including spare parts) accounted for 20.7% of
total sales, while consumables (plastic and reagents) accounted for 16.8%.
Research and development
Research and development expenses in 2016 amounted to 9.3% of sales (2015:
9.1%) or CHF 47.1 million (2015: CHF 39.9 million). All told, research and
development activities were CHF 51.9 million gross (2015: CHF 56.7 million). The
total figure also includes development programs for OEM instrument customers in
the Partnering Business (CHF 9.8 million) and capitalized development costs
(CHF 6.6 million). However, these costs were clearly exceeded by amortization
amounting to CHF 11.6 million.
Strong balance sheet - dividend unchanged
Tecan's equity ratio reached 66.3% as of December 31, 2016 (December
31, 2015: 68.7%). Net liquidity (cash and cash equivalents minus bank
liabilities and loans) increased to CHF 242.3 million (December 31, 2015: CHF
198.8 million). This figure includes the acquisition of SPEware Corporation with
a base purchase consideration of USD 50.0 million (CHF 49.0 million), of which
the net payable was fully paid in cash. The company's share capital was CHF
1,154,137 as at the reporting date of December 31, 2016 (December 31, 2015: CHF
1,146,758), consisting of 11,541,371 registered shares with a nominal value of
CHF 0.10.
The Board of Directors will propose an unchanged dividend of CHF 1.75 per share
to the shareholders at the Company's Annual General Meeting on April 11, 2017.
Outlook 2017
As previously communicated, Tecan expects in the mid-term to continue to
organically outgrow the market average and increase this growth rate through
acquisitions. For 2017, total Tecan Group sales are forecast to increase by at
least 6% in local currencies. The reported EBITDA margin is expected to further
expand to at least 18% of sales, including acquisition-related costs in a mid
single-digit million Swiss franc amount.
These expectations regarding profitability are based on an average exchange rate
forecast for full-year 2017 of one euro equaling CHF 1.07 and one US dollar
equaling CHF 0.99 and exclude future acquisitions.
Financial Report and Webcast
The full 2016 Financial Report can be accessed on the Company's website
www.tecan.com under Investor Relations. An iPad App for the Tecan Financial
Reports is also available from the App Store.
Tecan will hold an analyst and press conference to discuss the 2016 annual
results today at 9:00 a.m. (CET). The presentation will also be relayed by live
audio webcast, which interested parties can access at www.tecan.com. A link to
the webcast will be provided immediately prior to the event.
The dial-in numbers for the conference call are as follows:
For participants from Europe: +41 58 310 50 00 or +44 203 059 58 62 (UK)
For participants from the US: +1 631 570 5613
Participants should if possible dial in 15 minutes before the start of the
event.
Key upcoming dates
* The Annual General Meeting of Tecan's shareholders will take place in
Pfaeffikon, SZ, on April 11, 2017.
* The 2017 Interim Report will be published on August 16, 2017.
About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and
solutions in biopharmaceuticals, forensics and clinical diagnostics. The company
specializes in the development, production and distribution of automated
workflow solutions for laboratories in the life sciences sector. Its clients
include pharmaceutical and biotechnology companies, university research
departments, and forensic and diagnostic laboratories. As an original equipment
manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM
instruments and components that are then distributed by partner companies.
Founded in Switzerland in 1980, the company has manufacturing, research and
development sites in both Europe and North America and maintains a sales and
service network in 52 countries. Registered shares of Tecan Group are traded on
the SIX Swiss Exchange (TECN; ISIN CH0012100191).
For further information:
Tecan Group
Dr. Rudolf Eugster Martin Braendle
Chief Financial Officer Vice President, Communications &
Investor Relations
investor(at)tecan.com Tel. +41 (0) 44 922 84 30
www.tecan.com Fax +41 (0) 44 922 88 89
Press Release with financial tables:
http://hugin.info/100384/R/2087673/787930.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Tecan Group AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 15.03.2017 - 06:30 Uhr
Sprache: Deutsch
News-ID 530200
Anzahl Zeichen: 17297
contact information:
Town:
Maennedorf
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 200 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Full year 2016: Another year of double-digit sales growth for Tecan"
steht unter der journalistisch-redaktionellen Verantwortung von
Tecan Group AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
